Abstract
Previous neuroimaging studies suggest a negative relationship between the apolipoprotein (ApoE) ε4 allele and brain integrity in human immunodeficiency virus (HIV)-infected (HIV+) individuals, although the presence of this relationship across adulthood remains unclear. The purpose of this study is to clarify the discrepancies using a large, diverse group of HIV+ individuals and multiple imaging modalities sensitive to HIV. The association of ApoE ε4 with structural neuroimaging and magnetic resonance spectroscopy (MRS) was examined in 237 HIV+ individuals in the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study. Cortical and subcortical gray matter, abnormal and total white matter, ventricles, sulcal cerebrospinal fluid (CSF), and cerebellar gray matter, white matter, and CSF volumes, and MRS concentrations of myo-inositol, creatine, N-acetyl-aspartate, and choline in the frontal white matter (FWM), frontal gray matter (FGM), and basal ganglia were examined. Secondary analyses explored this relationship separately in individuals ≥50 years old (n = 173) and <50 years old (n = 63). No significant differences were observed between ApoE ε4+ (ApoE ε3/ε4 and ApoE ε4/ε4) individuals (n = 69) and ApoE ε4− (ApoE ε2/ε3 and ApoE ε3/ε3) individuals (n = 167). When individuals were further divided by age, no significant genotype group differences were identified in individuals <50 or ≥50 years of age on any neuroimaging outcome. The ApoE ε4 allele did not affect brain integrity in this large, diverse sample of HIV+ individuals. The effects of ApoE ε4 may not be apparent until more advanced ages and may be more prominent when present along with other risk factors for neuronal damage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ances BM, Ortega M, Vaida F, Heaps J, Paul RH (2012) Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr 59:469–477
Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL, CHARTER Group (2015) CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol 1:9
Becker JT, Martinson JJ, Penugonda S, Kingsley L, Molsberry S, Reynolds S, Aronow A, Goodkin K, Levine A, Martin E, Miller EN, Munro CA, Ragin A, Sacktor N (2014) No association between Apoε4 alleles, HIV infection, age, neuropsychological outcome, or death. J Neurovirol 21:24–31
Brummel SS, Singh KK, Maihofer AX, Farhad M, Qin M, Fenton T, Nievergelt CM, Spector SA (2016). Associations of genetically determined continental ancestry with CD4+ count and plasma HIV-1 RNA beyond self-reported race and ethnicity. JAIDS, Advance online publication. doi:10.1097/QAI.0000000000000883
Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK (2008) Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro and the APOE ε4/ε4 genotype accelerates HIV disease progression. PNAS 105:8718–8723
Chang L, Andres M, Sadino J, Jiang CS, Nakama H, Miller E, Ernst T (2011) Impact of apolipoprotein E ε4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage 58:1017–1027
Chang L, Jiang C, Cunningham E, Buchthal S, Douet V, Andres M, Ernst T (2014) Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits. Neurology 82:2213–2222
Cohen RA, Harezlak J, Schifitto G, Hana G, Clark U, Gongvatana A, Paul RH, Taylor M, Thompson P, Alger J, Brown M, Zhong J, Campbell T, Singer E, Daar E, McMahon D, Tso Y, Yiannoutsos CT, Navia B, HIV Neuroimaging Consortium (2010) Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol 16:25–32
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923
Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apoliprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155:487–495
Ernst T, Chang L, Arnold S (2003) Increased glial metabolites predict increased working memory network in HIV brain injury. Neuroimage 19:1686–1693
Fennema-Notestine C, Panizzon MS, Thompson WR, Chen CH, Eyler LT, Fischl B, Franz CE, Grant MD, Jak AJ, Jernigan TL, Lyons MJ, Neale MC, Seidman LJ, Tsuang MT, Xian H, Dale AM, Kremen WS (2011) Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis 26:49–60
Fennema-Notestine C, Ellis RJ, Archibald SL, Jernigan TL, Letendre SL, Notestine RJ, Taylor MJ, Theilmann RJ, Julaton MD, Croteau DJ, Wolfson T, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2013) Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 19:393–401
Fujimura JH, Rajagopalan R (2011) Different differences: the use of ‘genetic ancestry’ versus race in biomedical human genetic research. Soc Stud Sci 41:5–30
Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, Frank LR, Grant I, CHARTER Group (2009) White matter tract injury and cognitive impairment in HIV-infected individuals. J Neurovirol 15:187–195
Gongvatana A, Cohen RA, Correia S, Devlin KN, Miles J, Kang H, Ombao H, Navia B, Laidlaw DH, Tashima KT (2011) Clinical contributors to cerebral white matter integrity in HIV-infected individuals. J Neurovirol 17:477–486
Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia BA, HIV Neuroimaging Consortium (2011) Persistence of HIV-associated cognitive impairment, inflammation and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625–633
Heaps JM, Joska J, Hoare J, Ortega M, Agrawal A, Seedat S, Ances BM, Stein DJ, Paul RH (2012) Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol 18:151–156
Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096
Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV- associated neurocognitive disorder before and during the era of combination antiretroviral therapy: differences in rates, nature and predictors. J Neurovirol 17:3–16
Hoare J, Westgarth-Taylor J, Fouche JP, Combrinck M, Spottiswoode B, Stein DJ, Joska JA (2013) Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psychiatry Clin Neurosci 263:189–195
Hulgan T, Samuels DC, Bush W, Ellis RJ, Letendre SL, Heaton RK, Franklin DR, Straub P, Murdock DG, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, Kallianpur AR, CHARTER Study Group (2015) Mitochondrial DNA haplogroups and neurocognitive impairment during HIV infection. Clin Infect Dis 61:1476–1484
Jahanshad N, Valcour VG, Nir TM, Kohannim O, Busovaca E, Nicolas K, Thompson PM (2012) Disrupted brain networks in the aging HIV+ population. Brain Connectivity 2:335–344
Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Teilmann RJ, Julaton MD, Notestine RJ, Wolfson T, Letendre SL, Ellis RJ, Heaton RK, Gamst AC, Franklin DR Jr, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Grant I, CHARTER Group (2011) Clinical factors related to brain structure in HIV: the CHARTER study. J Neuroviol 17:248–257
Joska JA, Combrinck M, Valcour VG, Hoare J, Leisegang F, Mahne AC, Myer L, Stein DJ (2010) Assocation between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol 16:377–383
Kallianpur AR, Jia P, Ellis RJ, Zhao Z, Bloss C, Wen W, Marra CM, Hulgan T, Simpson DM, Morgello S, McArthur JC, Clifford DB, Collier AC, Gelman BB, McCutchan JA, Franklin D, Samuels DC, Rosario D, Holzinger E, Murdock DG, Letendre S, Grant I, CHARTER Study Group (2014) Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One 9:e103123
Kallianpur AR, Levine AJ (2014) Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep 11:336–352
Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G (2010) Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 9:8
Lin K, Taylor MJ, Heaton R, Franklin D, Jernigan T, Fennema-Notestine C, McCutchan A, Atkinson JH, Ellis RJ, McArthur J, Morgello S, Simpson D, Collier AC, Marra C, Gelman B, Clifford D, Grant I, group C (2011) Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol 33:326–334
Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RCP, Griffith P, Obisesan TO, Shatz R, Borenstein A, Cupples LA, Lunetta KL, Fallin MD, Baldwin CT, Farrer LA, Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (2011) A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 68:1569–1579
Martins CAR, Oulhaj A, de Jager CA, Williams JH (2005) APOE alleles predict the rate of cognitive decline in Alzheimer disease. Neurology 65:1888–1893
Masters MC, Ances BM (2014) Role of neuroimaging in HIV-associated neurocognitive disorders. Semin Neurol 34:89–102
Mersha TB, Abebe T (2015) Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Human Genomics 9:1–15
Morgan EE, Woods SP, Letendre SL, Franklin DR, Bloss C, Goate A, Heaton RK, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Ellis RJ, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, Vaida F, Clifford DB, CHARTER Group (2013) Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 19:150–16
Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, Unverzagt FW, Smith-Gamble V, Gao S, Hendrie HC, Hall KS (2006) Association of apolipoprotein E genotype and Alzheimer disease in African Americans. JAMA Neurology 63:431–434
Panos SE, Hinkin CH, Singer EJ, Thames AD, Patel SM, Sinsheimer JS, Del Re AC, Gelman BB, Morgello S, Moore DJ, Levine AJ (2013) Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: the modulating effects of older age and disease severity. Neurobehavioral HIV Medicine 5:11–22
Pfefferbaum A, Rogosa DA, Rosenbloom MJ, Chu W, Sassoon SA, Kemper CA, Deresinski S, Rohlfing T, Zahr NM, Sullivan EV (2014) Accelerated aging of selective brain structures in HIV infection: a controlled, longitudinal MRI study. Neurobiol Aging 35:1755–1768
Pomara N, Crandall DT, Choi SJ, Johnson G, Lim KO (2001) White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res Neuroimaging 106:15–24
Provencher SW (2001) Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 14:260–264
Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142
Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077
Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR (2007) Brain structural alterations before mild cognitive impairment. Neurology 68:1268–1273
Spector SA, Singh KK, Gupta S, Cystique LA, Jin H, Letendre S, Schrier R, Wu Z, Hong KX, Yu X, Shi C, Heaton RK, HNRC Group (2010) 195APOE ε4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors from Anhui province. China AIDS 24:1471–1479
Stebbins GT, Smith CA, Bartt RE, Kessler HA, Adeyemi OM, Martin E, Cox JL, Bammer R, Moseley ME (2007) HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging study. JAIDS 46:564–573
Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, McCutchan JA, Wallace MR, Atkinson JH, Grant I, HIV Neurobehavioral Research Center Group (1998) Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Neurology 55:161–168
Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L (2010) Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol 16:115–124
Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, GIulianelli M, Galgani S, Antinori A, Narciso P (2007) Persistance of neuropsychological deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45:174–182
Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes OA, Grove J, Liu Y, Abdul-Majid KB, Gartner S, Sacktor N (2004) Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii aging and HIV cohort. J Neuroimmunol 157:197–202
Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AC P, Pumpradit W, Shlay JC, El-Sadr W, Price RW, INSIGHT SMART Study Group (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873
Wright PW, Heaps J, Shimony JS, Thomas JB, Ances BM (2012) The effects of HIV and combination antiretroviral therapy on white matter integrity. AIDS 26:1501–1508
Acknowledgments
The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER; https://www.charterresource.ucsd.edu) is supported by awards N01 MH22005, HHSN271201000036C, and HHSN271201000030C from the National Institutes of Health (NIH). This work was also supported by P30 MH62512 and R01NR012657 (BMA), R01NR012907 (BMA), and R01NR014449 (BMA). The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with Johns Hopkins University; the Icahn School of Medicine at Mount Sinai; University of California, San Diego; University of Texas, Galveston; University of Washington, Seattle; and Washington University, St. Louis and is headquartered at the University of California, San Diego and includes the following: Director: Igor Grant, M.D.; Co-Directors: Scott L. Letendre, M.D., Ronald J. Ellis, M.D., Ph.D., Thomas D. Marcotte, Ph.D.; Center Manager: Donald Franklin, Jr.; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D.; Laboratory and Virology Component: Scott Letendre, M.D. (Co-P.I.), Davey M. Smith, M.D. (Co-P.I.).; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., Matthew Dawson; Imaging Component: Christine Fennema-Notestine, Ph.D. (P.I.), Michael J Taylor, Ph.D., Rebecca Theilmann, Ph.D.; Data Management Component: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman; Statistics Component: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D., Reena Deutsch, Ph.D.; Johns Hopkins University Site: Ned Sacktor (P.I.), Vincent Rogalski; Icahn School of Medicine at Mount Sinai Site: Susan Morgello, M.D. (Co-P.I.) and David Simpson, M.D. (Co-P.I.), Letty Mintz, N.P.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.), Kaori Phillips, B.S.N.; University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Sher Storey, PA-C.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.D. (P.I.), Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., Mengesha Teshome, M.D. The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Government.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
All procedures were approved by the Institutional Review Boards of each CHARTER site, and all participants provided written informed consent.
Conflict of Interest
The authors declare that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Cooley, S.A., Paul, R.H., Fennema-Notestine, C. et al. Apolipoprotein E ε4 genotype status is not associated with neuroimaging outcomes in a large cohort of HIV+ individuals. J. Neurovirol. 22, 607–614 (2016). https://doi.org/10.1007/s13365-016-0434-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-016-0434-7